Meta Biomed Co., Ltd.
Financials
Valuation Metrics
Meta Biomed Co., Ltd.'s Market Cap is ₩1026B. At end of 2025 it was ₩1350B. Ranked #1267 of 2,421 in KR market (top 52%), #689 of 1,640 on KOSDAQ (top 42%), #45 of 96 in Health Care Equipment & Services (top 47%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 102.57B KRW | KR#1,267/2,421 Sec#45/96 |
| Revenue | 101.19B KRW | KR#1,408/2,421 Sec#36/96 |
| Net Income | 16.70B KRW | KR#779/2,421 Sec#20/96 |
| Total Assets | 194.62B KRW | KR#1,334/2,421 Sec#36/96 |
| Net Assets | 130.38B KRW | KR#1,233/2,421 Sec#36/96 |
| Employees | 296 | KR#801/2,421 Sec#23/96 |
| Value | ||
| P/E | 6.14x | KR#471/2,421 Sec#10/96 |
| P/B | 0.79x | KR#1,244/2,421 Sec#30/96 |
| PEG | 0.02x | KR#189/2,421 Sec#9/96 |
| P/S | 1.01x | KR#1,403/2,421 Sec#29/96 |
| FCF Yield | -0.46% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | 12.81% | KR#423/2,421 Sec#17/96 |
| ROA | 8.58% | KR#383/2,421 Sec#22/96 |
| Op. Margin | 18.91% | KR#183/2,421 Sec#15/96 |
| Revenue Growth | 1.82% | KR#1,406/2,421 Sec#71/96 |
| Earnings Growth | 287.42% | KR#174/2,421 Sec#10/96 |
| Financial Health | ||
| Debt Ratio | 49.27% | KR#952/2,421 Sec#53/96 |
| FCF | -471.2M KRW | KR#1,251/2,421 Sec#36/96 |
| Cash | 15.31B KRW | KR#1,410/2,421 Sec#40/96 |
| Current Ratio | 1.53x | KR#1,174/2,421 Sec#64/96 |
| Dividend | ||
| Div. Yield | 2.77% | KR#685/2,421 Sec#13/96 |
| Div. Growth | 250.00% | KR#38/2,421 Sec#2/96 |
| Performance | ||
| 1Y Return | -39.50% | KR#1,820/2,421 Sec#57/96 |
| 1M Return | -6.33% | KR#1,892/2,421 Sec#63/96 |
| From 52W High | -42.80% | KR#1,052/2,421 Sec#31/96 |
| 1Y MDD | -48.08% | KR#907/2,421 Sec#31/96 |
| Trading | ||
| Volume | 37,950 shares | KR#1,262/2,421 Sec#44/96 |
| Trading Value | 143.0M KRW | KR#1,397/2,421 Sec#59/96 |
| Foreign Own. | 5.31% | KR#821/2,421 Sec#27/96 |
| Per Share | ||
| EPS | 615 KRW | KR#911/2,421 Sec#22/96 |
| BPS | 4,798 KRW | KR#1,528/2,421 Sec#39/96 |
Company Info
Meta Biomed, established in 1990 and listed on KOSDAQ in 2008, researches, develops, produces, and sells medical devices, including dental materials and suture raw threads. The company has secured a global network with two production and four sales bases, expanding into medical fields by utilizing biocompatible polymer materials. It aims to diversify its medical material business and stabilize its profit structure by developing polymer fillers as a new venture. Meta Biomed was established in 1999 and is headquartered in Cheongju, Chungcheongbuk-do.